You are all amped up to run a western blot to identify “your favorite protein.” The lysates have been run and proteins separated by SDS-PAGE. Now it’s time to transfer proteins from the gel to the membrane, and you’re sitting wondering….wet or semi-dry?? Or maybe you are better prepared than I was as a graduate student and you already know your next step, in which case you are aware of the pros and cons of wet and semi-dry transfer.
Characterize Myeloid Cell Mediated Immunosuppression in the Tumor Microenvironment Using Multiplex IHC
The clinical validation of immune checkpoint inhibitors as immunotherapeutic agents for a variety of cancers has revolutionized the field of cancer therapy. While significant improvement in patient outcome has been observed with previously untreatable tumors, not all patients respond to these drugs (1). An advanced understanding of the immune regulatory context of the tumor microenvironment (TME) is required to harness the power of the antitumor immune response. This will allow identification of novel therapeutic targets and potential biomarkers that can predict response to therapy (2, 3).
Our mIHC application notes and poster resources explore the protocol and technical considerations for selecting and using antibodies in mIHC to assess immunosuppression mediated by myeloid cells in FFPE tissue samples.
Type 2 diabetes is a growing epidemic, and is recognized as one of the most serious metabolic disease worldwide. A multifactorial disease, type 2 diabetes is a perfect example of metabolic miscommunication between different organs resulting in a pathological outcome. According to CDC in the United States, 29.1 million people in the United States have diabetes, and 8.1 million may be undiagnosed. The disease affects more than 1 in every 10 adults, and seniors aged 65 and above are most affected. What makes the disease morbid are the secondary complications associated with it; atherosclerosis and cardiomyopathy are the leading cause of death in people diagnosed with type 2 diabetes. The need for an effective treatment has become a global health priority.
You are glaring at your computer screen with a million thoughts in your head. You just got back the reviewers’ comments on your first manuscript. You don’t know where to start or how to respond. You are angry, frustrated, but mostly confused. The manuscript was supposed to be perfect, how could anyone find anything wrong with it? What you might not realize is that this reaction is normal . . .